Wimus, they have to partner/sell out something ! If they don't, after likely no go @PDUFA date (in whichever form) we will be at much lower prices than today.
The only acceptable (to me) dilution is with a strategic partner (in the like INCYTE did with Agenus) : in our case, 5-10 mln shares @ 1.00 subscribed by the new partner.
A dilution with new shares in favour of a financial player will destroy us.
The only relevant number that matters is how much SeroquelXR Mallinkrodt ordered from and paid IPCI for.
If you feel that Mallinkrodt didn't come close to the Mackie and Maxim analyst estimates as it pertains to their deal with IPCI so be it...but there's zero reason to believe that Mallinkrodt didn't launch SeroquelXR the same way they launch all their drugs, which means they'd have to have a built up ample supply of SeroquelXR on hand to start penetrating their anticipated target market with.
As for a $5M offering...who knows...all I know is that in the absence of any facts to suggest otherwise...IPCI themselves projected that they would be attaining positive net income sometime in the back half of this year...and at these already depressed share prices it's illogical to assume that the newly appointed CFO's 1st order of biz would be to destroy the already depressed market price further.
News 
Market Data 
Discover 
AI
